Propanc Biopharma, Inc.
PPCB · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $57 | $1 | $2 | $2 |
| SG&A Expenses | $57 | $1 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $57 | $2 | $2 | $2 |
| Operating Income | -$57 | -$2 | -$2 | -$2 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$2 | -$0 | -$1 | -$1 |
| Pre-Tax Income | -$59 | -$2 | -$3 | -$3 |
| Tax Expense | $0 | -$0 | -$0 | -$0 |
| Net Income | -$59 | -$2 | -$3 | -$3 |
| % Margin | – | – | – | – |
| EPS | -14.85 | -1,420.95 | -31,268.39 | -1,119,475.67 |
| % Growth | 99% | 95.5% | 97.2% | – |
| EPS Diluted | -14.85 | -1,200 | -31,268.39 | -1,119,475.67 |
| Weighted Avg Shares Out | 4 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 4 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$58 | -$1 | -$2 | -$2 |
| % Margin | – | – | – | – |